State Drug Alert: 148 Medicine Samples Fail CDSCO Quality Tests in October We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Alkem Vs Alchem: Delhi HC Grants Interim Relief to Alkem Labs in Trademark Tussle We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Haryana-based Alchem International on Thursday moved the division bench of the Delhi High Court, challenging a single-judge’s decision restraining it from selling, manufacturing or dealing with any pharmaceutical product using the name ‘Alchem’, or any other name similar to Mumbai-based Alkem Laboratories‘ ‘Alkem’ trademark till further orders. A division bench comprising Justices C. Hari Shankar…
Alkem Labs Gets CDSCO Panel Nod for conducting Phase III study of Semaglutide tablet We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Alkem Laboratories on Monday said it has launched a biosimilar product in India for the treatment of breast cancer. The company has introduced Pertuza injection 420mg/14mL, a pertuzumab biosimilar, for the treatment of HER2-positive breast cancer, the drug firm said in a statement. Alkem’s Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab, it…
NPPA Fixes Retail Prices of 42 Formulations Including Amoxycillin, Dapagliflozin, Cefixime We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Alkem Launches Olesoft Trucera Lotion to Repair Skin Barrier, Boost Hydration We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link